Rheumatic Joint Disease clinical trials at University of California Health
1 research study open to eligible people
open to eligible people ages up to 21 years
Continuation of the CARRA Registry as described in the protocol will support data collection on patients with pediatric-onset rheumatic diseases. The CARRA Registry will form the basis for future CARRA studies. In particular, this observational registry will be used to answer pressing questions about therapeutics used to treat pediatric rheumatic diseases, including safety questions.
at UCLA UCSF
Our lead scientists for Rheumatic Joint Disease research studies include Susan Kim, MD.